REGENERON PHARMACEUTICALS, INC. — Director's Dealing 2021

Nov 19, 2021

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: REGENERON PHARMACEUTICALS, INC. (REGN)
CIK: 0000872589
Period of Report: 2021-11-19

Reporting Person: SCHLEIFER LEONARD S (Director, President & CEO)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2021-11-19	Common Stock	M	239063	$270.43	Acquired	543809	Direct
2021-11-19	Common Stock	F	173491	$651.96	Disposed	370318	Direct
2021-11-19	Common Stock	M	281250	$179.13	Acquired	651568	Direct
2021-11-19	Common Stock	F	185646	$651.96	Disposed	465922	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2021-11-19	Non-Qualified Stock Option (right to buy)	$179.13	M	281250	Disposed	2022-12-14	Common Stock (281250)	Direct
2021-11-19	Non-Qualified Stock Option (right to buy)	$270.43	M	239063	Disposed	2023-12-13	Common Stock (239063)	Direct

Holdings (Non-Derivative)

Security	Shares	Ownership
Common Stock	200000	Indirect
Common Stock	5874	Indirect
Common Stock	21178	Indirect

Footnotes

F1: These shares are held in a trust for the benefit of the reporting person's family members. The reporting person's spouse is a trustee of the trust.

F2: The stock option award vests in four equal annual installments, commencing one year after the date of grant.